Cardiovascular Outcomes With Dupilumab Versus Omalizumab in Severe Asthma
Summary Cardiovascular safety comparisons among asthma biologics remain limited. Dupilumab and omalizumab showed comparable cardiovascular outcomes in severe asthma.
Authors
- James Cheng‐Chung Wei (ORCID: https://orcid.org/0000-0002-1235-0679)
- Po‐Cheng Shih (ORCID: https://orcid.org/0000-0003-4152-9296)
- Chun‐Ting Lin (ORCID: https://orcid.org/0009-0004-0701-5309)
Institutions
- Asia University (TW)
- China Medical University (TW)
- Taichung Veterans General Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- Changhua Christian Hospital (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-09-06
- DOI
- https://doi.org/10.1111/cea.70413
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00